Chemistry:Phenylpiracetam hydrazide
From HandWiki
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| Trade names | Phenylpiracetam hydrazide |
| Other names | Fonturacetam hydrazide |
| Pregnancy category |
|
| Routes of administration | Oral |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C12H15N3O2 |
| Molar mass | 233.271 g·mol−1 |
| 3D model (JSmol) | |
| Chirality | Racemic mixture |
| |
| |
  (what is this?) (verify) | |
Phenylpiracetam hydrazide, also known as fonturacetam hydrazide,[1] is a racetam that is a derivative of phenylpiracetam in which the amide group is replaced with a hydrazide group. It was first reported by a Russian research group in 1980 as part of a series of chemical compounds investigated as anticonvulsants.[2] In an electroshock test it was found to have an ED50 of 310 mg/kg.[2]
Sale on the internet
All piracetam derivatives are not permitted to be sold as dietary supplements in the United States.[3] However, because they lack scheduling, piracetam derivatives like phenylpiracetam hydrazide are sold over the clear net accompanied by indications stating that the compound is "not for human consumption".[4]
See also
References
- ↑ "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 63". WHO Drug Information 24 (1): 56. 2010. http://apps.who.int/medicinedocs/documents/s17753en/s17753en.pdf. Retrieved 26 November 2015.
- ↑ 2.0 2.1 "Synthesis and anticonvulsive activity of 4-phenyl-2-pyrrolidinone-1-acetic acid amides" (in ru). Khimiko-Farmatsevticheskii Zhurnal 14 (11): 43–48. 1980.
- ↑ "Presence of Piracetam in Cognitive Enhancement Dietary Supplements". JAMA Internal Medicine 180 (3): 458–459. March 2020. doi:10.1001/jamainternmed.2019.5507. PMID 31764936.
- ↑ ""Not for human consumption": a review of emerging designer drugs". Pharmacotherapy 34 (7): 745–757. July 2014. doi:10.1002/phar.1424. PMID 24710806.
 |  |
